clinical trial · NCT05338346
A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies
Antengene Discovery Limited·phase1·terminated·n = 22
Advanced Solid TumorsHematological MalignanciesATG-018
brief summary
This is a Phase I, Open-Label, Multi-Center, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-018 (ATR inhibitor) Treatment in Patients with Advanced Solid Tumors and Hematological Malignancies .
started
Jul 8, 2022
primary completion
Jan 8, 2024
completion
Jan 8, 2024
last updated
Jul 18, 2024
detailed description
This is a Phase I, multi-center, open-label study of ATG-018 administered orally as monotherapy in patients with advanced solid tumors and hematological malignancies. The study design includes a Dose Escalation Phase and a Dose Expansion Phase.
official title
A Phase I, Open-Label, Multi-Center, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol